Periodic Fever Syndrome Market: Global industry analysis and forecast 2016 - 2024


  • To Be Published : Feb-2017 |
  • Status : Work in progress |
  • Format :

Periodic Fever Syndrome are autoinflammatory diseases which cause episodic illness and do not have an infectious cause. Periodic Fever Syndrome are genetic and are also present during childhood. It is defined by the various genetic defects, by the clinical features of the syndrome, the affected part of the body, age of the patient and the area of the world from where the patient belongs. Treatment is based on the understanding of the gene defect. Despite similarities in symptoms, periodic fever syndrome has different patterns of inheritance, causes, length and frequency of ‘attacks.' Some of the chronic condition associated with Periodic Fever Syndrome includes Cryopyrin-associated periodic syndrome (CAPS), hyperimmunoglobulinemia D syndrome (HIDS), TNF receptor-associated periodic syndrome (TRAPS) and Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis Syndrome (PFAPA). The symptoms of Periodic Fever Syndrome are cyclic in nature, coming and going, with the difference in severity.

Periodic Fever Syndrome affects many organs and tissues and has its own set of symptoms along with high temperature during attacks. Elevated serum levels of acute-phase reactants such as fibrinogen and serum amyloid A, leukocytosis and high level of erythrocyte sedimentation rate (ESR) are associated with periodic fever syndrome.

Diagnostic tools and genetic test are available for patients with periodic fever. For some conditions such as Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis Syndrome (PFAPA), no genetic test are available yet. Hereditary periodic fever syndromes (HPFSs) are rare and is characterized by short and recurrent attacks. These attacks undergo remission without the use of antibiotic, anti-inflammatory, or immunosuppressive treatment. The patient feels healthy and is back to its daily routine until the next episode of periodic fever occurs.

Previously, there was no approved medicine for the treatment of TNF Receptor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulinemia D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD). In September 2016, the US Food and Drug Administration (FDA) has granted Novartis’ ilaris (canakinumab) expanded use for the treatment of these three rare and distinct types of Periodic Fever Syndromes.Treatment with oral anti-inflammatory drugs, e.g. corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), helps to control the symptoms but does not assist in the prevention of Periodic Fever Syndrome.

The global periodic fever syndrome is segmented on the basis of indication, treatment, end user, and geography:

Segmentation by Indication

  • Hyperimmunoglobulinemia D Syndrome (HIDS)
  • Familial Mediterranean Fever (FMF)
  • TNF Receptor-Associated Periodic Syndrome (TRAPS)
  • Cryopyrin-Associated Periodic Syndrome (CAPS)
  • Others

Segmentation by Treatment

  • Oral anti-inflammatory drugs (corticosteroid)
  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Anti-TNF therapy
  • Statins
  • Others

Segmentation by End User

  • Hospitals
  • Retail pharmacy

Based on the Indication, the global periodic fever syndrome market is segmented into Familial Mediterranean Fever (FMF), Cryopyrin-Associated Periodic Syndrome (CAPS), Hyperimmunoglobulinemia D Syndrome (HIDS) and TNF Receptor-Associated Periodic Syndrome (TRAPS). Familial Mediterranean fever is less common in other ethnic groups compared to people of Eastern Mediterranean ancestry. TNF Receptor-Associated Periodic Syndrome and Hyperimmunoglobulinemia D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) are less common among people and is estimated to affect around 1-2 people per million (Mn). Expansion of the clinical pipeline by companies and the greater focus on patient care and monitoring have been the major strategies adopted by major players to fuel growth within the forecast period of 2016-2024 in the global Periodic Fever Syndrome Market. Key challenges faced by the market is limited knowledge, and limited treatment options as periodic fever syndrome is a rare disease. There is difficulty in the diagnosis of periodic fever syndrome due to unrelated symptoms.

On the basis of geography, global periodic fever syndrome market is segmented into five key regions i.e. North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa. North America is expected to dominate the global Periodic Fever Syndrome Market due to high demand from U.S.

Some of the major players in global Periodic Fever Syndrome Market are Novartis AG, Simvastatin, Merck & Co., Inc., Swedish Orphan Biovitrum AB.

The report covers exhaustive analysis on:

  • Periodic Fever Syndrome Market Segments
  • Periodic Fever Syndrome Market Dynamics
  • Historical Actual Market Size, 2013 - 2015
  • Periodic Fever Syndrome Market Size & Forecast 2016 to 2024
  • Periodic Fever Syndrome Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Periodic Fever Syndrome Market Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance
Back To Top